{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:39:31Z","timestamp":1759333171717,"version":"3.37.3"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00428-024-03752-5","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T06:02:30Z","timestamp":1708754550000},"page":"733-742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact"],"prefix":"10.1007","volume":"484","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1363-8559","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Coca-Pelaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P.","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Agaimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Nuyts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory W.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Vander Poorten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz P.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Civantos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Zafereo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti A.","family":"M\u00e4kitie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oded","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain J.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-6709","authenticated-orcid":false,"given":"Alessandra","family":"Rinaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-8002","authenticated-orcid":false,"given":"Alfio","family":"Ferlito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"3752_CR1","volume-title":"WHO classification of tumours of endocrine organs","author":"R Lloyd","year":"2017","unstructured":"Lloyd R, Osamura R, Kl\u00f6ppel G, Rosai J (2017) WHO classification of tumours of endocrine organs. International Agency for Research on Cancer, Lyon"},{"key":"3752_CR2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s00268-007-9033-3","volume":"31","author":"EM Sanders","year":"2007","unstructured":"Sanders EM, LiVolsi VA, Brierley J et al (2007) An evidence-based review of poorly differentiated thyroid cancer. World J Surg 31:934\u2013945. https:\/\/doi.org\/10.1007\/s00268-007-9033-3","journal-title":"World J Surg"},{"key":"3752_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/modpathol.2010.117","volume":"23","author":"S Asioli","year":"2010","unstructured":"Asioli S, Erickson LA, Righi A et al (2010) Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol 23:1269\u20131278. https:\/\/doi.org\/10.1038\/modpathol.2010.117","journal-title":"Mod Pathol"},{"key":"3752_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/thy.2018.0509","volume":"29","author":"T Ibrahimpasic","year":"2019","unstructured":"Ibrahimpasic T, Ghossein R, Shah JP, Ganly I (2019) Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid 29:311\u2013321. https:\/\/doi.org\/10.1089\/thy.2018.0509","journal-title":"Thyroid"},{"key":"3752_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/thy.2012.0403","volume":"23","author":"T Ibrahimpasic","year":"2013","unstructured":"Ibrahimpasic T, Ghossein R, Carlson DL et al (2013) Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986\u20132009 Memorial Sloan-Kettering Cancer Center experience. Thyroid 23:997\u20131002. https:\/\/doi.org\/10.1089\/thy.2012.0403","journal-title":"Thyroid"},{"issue":"525\u2013538","key":"3752_CR6","doi-asserted-by":"publisher","first-page":"xi","DOI":"10.1016\/j.ecl.2008.02.003","volume":"37","author":"RL Neff","year":"2008","unstructured":"Neff RL, Farrar WB, Kloos RT, Burman KD (2008) Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 37(525\u2013538):xi. https:\/\/doi.org\/10.1016\/j.ecl.2008.02.003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3752_CR7","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0021","volume":"11","author":"J Tong","year":"2022","unstructured":"Tong J, Ruan M, Jin Y et al (2022) Poorly differentiated thyroid carcinoma: a clinician\u2019s perspective. Eur Thyroid J 11:e220021. https:\/\/doi.org\/10.1530\/ETJ-22-0021","journal-title":"Eur Thyroid J"},{"key":"3752_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/cyt.12497","volume":"28","author":"C Saglietti","year":"2017","unstructured":"Saglietti C, Onenerk AM, Faquin WC et al (2017) FNA diagnosis of poorly differentiated thyroid carcinoma. A review of the recent literature. Cytopathology 28:467\u2013474. https:\/\/doi.org\/10.1111\/cyt.12497","journal-title":"Cytopathology"},{"key":"3752_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/MOO.0000000000000037","volume":"22","author":"KN Patel","year":"2014","unstructured":"Patel KN, Shaha AR (2014) Poorly differentiated thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 22:121\u2013126. https:\/\/doi.org\/10.1097\/MOO.0000000000000037","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"3752_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/107327480601300206","volume":"13","author":"KN Patel","year":"2006","unstructured":"Patel KN, Shaha AR (2006) Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13:119\u2013128. https:\/\/doi.org\/10.1177\/107327480601300206","journal-title":"Cancer Control"},{"key":"3752_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/PAP.0b013e3181b50640","volume":"16","author":"M Bongiovanni","year":"2009","unstructured":"Bongiovanni M, Sadow PM, Faquin WC (2009) Poorly differentiated thyroid carcinoma: a cytologic-histologic review. Adv Anat Pathol 16:283\u2013289. https:\/\/doi.org\/10.1097\/PAP.0b013e3181b50640","journal-title":"Adv Anat Pathol"},{"key":"3752_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF02176714","volume":"189","author":"T Langhans","year":"1907","unstructured":"Langhans T (1907) \u00dcber die epithelialen Formen der malignen Struma. Virchows Arch 189:69\u2013188","journal-title":"Virchows Archivs"},{"key":"3752_CR13","first-page":"650","volume":"116","author":"DK Granner","year":"1963","unstructured":"Granner DK, Buckwalter JA (1963) Poorly differentiated carcinoma of the thyroid gland. Surg Gynecol Obstet 116:650\u2013656","journal-title":"Surg Gynecol Obstet"},{"key":"3752_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.semdp.2020.03.003","volume":"37","author":"B Xu","year":"2020","unstructured":"Xu B, Ghossein R (2020) Poorly differentiated thyroid carcinoma. Semin Diagn Pathol 37:243\u2013247. https:\/\/doi.org\/10.1053\/j.semdp.2020.03.003","journal-title":"Semin Diagn Pathol"},{"key":"3752_CR15","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1002\/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x","volume":"52","author":"A Sakamoto","year":"1983","unstructured":"Sakamoto A, Kasai N, Sugano H (1983) Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849\u20131855. https:\/\/doi.org\/10.1002\/1097-0142(19831115)52:10%3c1849::aid-cncr2820521015%3e3.0.co;2-x","journal-title":"Cancer"},{"key":"3752_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00000478-198409000-00005","volume":"8","author":"ML Carcangiu","year":"1984","unstructured":"Carcangiu ML, Zampi G, Rosai J (1984) Poorly differentiated (\u201cinsular\u201d) thyroid carcinoma. A reinterpretation of Langhans\u2019 \u201cwuchernde Struma.\u201d Am J Surg Pathol 8:655\u2013668. https:\/\/doi.org\/10.1097\/00000478-198409000-00005","journal-title":"Am J Surg Pathol"},{"key":"3752_CR17","volume-title":"WHO classification of tumours of endocrine organs","author":"RA Delellis","year":"2004","unstructured":"Delellis RA, Lloyd RV, Heitz PU, Eng C (2004) WHO classification of tumours of endocrine organs, 3rd edn. International Agency for Research on Cancer (IARC), Lyon","edition":"3rd"},{"key":"3752_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/cncr.21739","volume":"106","author":"D Hiltzik","year":"2006","unstructured":"Hiltzik D, Carlson DL, Tuttle RM et al (2006) Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106:1286\u20131295. https:\/\/doi.org\/10.1002\/cncr.21739","journal-title":"Cancer"},{"key":"3752_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/cncr.20087","volume":"100","author":"M Volante","year":"2004","unstructured":"Volante M, Landolfi S, Chiusa L et al (2004) Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 100:950\u2013957. https:\/\/doi.org\/10.1002\/cncr.20087","journal-title":"Cancer"},{"key":"3752_CR20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/PAS.0b013e3180309e6a","volume":"31","author":"M Volante","year":"2007","unstructured":"Volante M, Collini P, Nikiforov YE et al (2007) Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31:1256\u20131264. https:\/\/doi.org\/10.1097\/PAS.0b013e3180309e6a","journal-title":"Am J Surg Pathol"},{"key":"3752_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA et al (2022) Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 33:27\u201363. https:\/\/doi.org\/10.1007\/s12022-022-09707-3","journal-title":"Endocr Pathol"},{"key":"3752_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/PAP.0000000000000368","volume":"30","author":"NP Ohori","year":"2023","unstructured":"Ohori NP, Nishino M (2023) Follicular neoplasm of thyroid revisited: current differential diagnosis and the impact of molecular testing. Adv Anat Pathol 30:11\u201323. https:\/\/doi.org\/10.1097\/PAP.0000000000000368","journal-title":"Adv Anat Pathol"},{"key":"3752_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/his.14550","volume":"80","author":"B Xu","year":"2022","unstructured":"Xu B, David J, Dogan S et al (2022) Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology 80:322\u2013337. https:\/\/doi.org\/10.1111\/his.14550","journal-title":"Histopathology"},{"key":"3752_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/cncr.23515","volume":"113","author":"M Rivera","year":"2008","unstructured":"Rivera M, Ghossein RA, Schoder H et al (2008) Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 113:48\u201356. https:\/\/doi.org\/10.1002\/cncr.23515","journal-title":"Cancer"},{"key":"3752_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12022-021-09674-1","volume":"32","author":"T Odate","year":"2021","unstructured":"Odate T, Oishi N, Kawai M et al (2021) Progression of papillary thyroid carcinoma to anaplastic carcinoma in metastatic lymph nodes: solid\/insular growth and hobnail cell change in lymph nodes are predictors of subsequent anaplastic transformation. Endocr Pathol 32:347\u2013356. https:\/\/doi.org\/10.1007\/s12022-021-09674-1","journal-title":"Endocr Pathol"},{"key":"3752_CR26","doi-asserted-by":"publisher","first-page":"eabf3657","DOI":"10.1126\/sciadv.abf3657","volume":"7","author":"H Luo","year":"2021","unstructured":"Luo H, Xia X, Kim GD et al (2021) Characterizing dedifferentiation of thyroid cancer by integrated analysis. Sci Adv 7:eabf3657. https:\/\/doi.org\/10.1126\/sciadv.abf3657","journal-title":"Sci Adv"},{"key":"3752_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12022-020-09638-x","volume":"31","author":"JM Cameselle-Teijeiro","year":"2020","unstructured":"Cameselle-Teijeiro JM, Eloy C, Sobrinho-Sim\u00f5es M (2020) Pitfalls in challenging thyroid tumors: emphasis on differential diagnosis and ancillary biomarkers. Endocr Pathol 31:197\u2013217. https:\/\/doi.org\/10.1007\/s12022-020-09638-x","journal-title":"Endocr Pathol"},{"key":"3752_CR28","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1097\/PAS.0000000000001967","volume":"46","author":"JA Barletta","year":"2022","unstructured":"Barletta JA, Gilday SD, Afkhami M et al (2022) NUTM1 -rearranged carcinoma of the thyroid\u202f: a distinct subset of NUT carcinoma characterized by frequent NSD3 - NUTM1 fusions. Am J Surg Pathol 46:1706\u20131715. https:\/\/doi.org\/10.1097\/PAS.0000000000001967","journal-title":"Am J Surg Pathol"},{"key":"3752_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/thy.2000.10.19","volume":"10","author":"F Basolo","year":"2000","unstructured":"Basolo F, Pisaturo F, Pollina LE et al (2000) N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19\u201323. https:\/\/doi.org\/10.1089\/thy.2000.10.19","journal-title":"Thyroid"},{"key":"3752_CR30","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.3390\/cancers13143627","volume":"13","author":"JN Nilsson","year":"2021","unstructured":"Nilsson JN, Siikanen J, Hedman C et al (2021) Pre-therapeutic measurements of iodine avidity in papillary and poorly differentiated thyroid cancer reveal associations with thyroglobulin expression, histological variants and Ki-67 index. Cancers (Basel) 13:3627. https:\/\/doi.org\/10.3390\/cancers13143627","journal-title":"Cancers (Basel)"},{"key":"3752_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1046\/j.1365-2559.2003.01642.x","volume":"42","author":"AS Rocha","year":"2003","unstructured":"Rocha AS, Soares P, Fonseca E et al (2003) E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42:580\u2013587. https:\/\/doi.org\/10.1046\/j.1365-2559.2003.01642.x","journal-title":"Histopathology"},{"key":"3752_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1186\/s12935-021-02344-6","volume":"21","author":"X Zhu","year":"2021","unstructured":"Zhu X, Wang X, Gong Y, Deng J (2021) E-cadherin on epithelial-mesenchymal transition in thyroid cancer. Cancer Cell Int 21:695. https:\/\/doi.org\/10.1186\/s12935-021-02344-6","journal-title":"Cancer Cell Int"},{"key":"3752_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12022-023-09752-6","volume":"34","author":"V Cracolici","year":"2023","unstructured":"Cracolici V, Cipriani NA (2023) High-grade non-anaplastic thyroid carcinomas of follicular cell origin: a review of poorly differentiated and high-grade differentiated carcinomas. Endocr Pathol 34:34\u201347. https:\/\/doi.org\/10.1007\/s12022-023-09752-6","journal-title":"Endocr Pathol"},{"key":"3752_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12022-021-09665-2","volume":"32","author":"M Volante","year":"2021","unstructured":"Volante M, Lam AK, Papotti M, Tallini G (2021) Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know? Endocr Pathol 32:63\u201376. https:\/\/doi.org\/10.1007\/s12022-021-09665-2","journal-title":"Endocr Pathol"},{"key":"3752_CR35","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L et al (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052\u20131066. https:\/\/doi.org\/10.1172\/JCI85271","journal-title":"J Clin Invest"},{"key":"3752_CR36","first-page":"2029","volume":"35","author":"V Sykorova","year":"2015","unstructured":"Sykorova V, Dvorakova S, Vcelak J et al (2015) Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing. Anticancer Res 35:2029\u20132036","journal-title":"Anticancer Res"},{"key":"3752_CR37","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-17-0871","volume":"17","author":"H Chen","year":"2018","unstructured":"Chen H, Luthra R, Routbort MJ et al (2018) Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 17:1575\u20131584. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0871","journal-title":"Mol Cancer Ther"},{"key":"3752_CR38","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1158\/1078-0432.CCR-17-1183","volume":"23","author":"T Ibrahimpasic","year":"2017","unstructured":"Ibrahimpasic T, Xu B, Landa I et al (2017) Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. Clin Cancer Res 23:5970\u20135980. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1183","journal-title":"Clin Cancer Res"},{"key":"3752_CR39","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","volume":"98","author":"I Landa","year":"2013","unstructured":"Landa I, Ganly I, Chan TA et al (2013) Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562-1566. https:\/\/doi.org\/10.1210\/jc.2013-2383","journal-title":"J Clin Endocrinol Metab"},{"key":"3752_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.path.2019.08.002","volume":"12","author":"MR Haroon Al Rasheed","year":"2019","unstructured":"Haroon Al Rasheed MR, Xu B (2019) Molecular alterations in thyroid carcinoma. Surg Pathol Clin 12:921\u2013930. https:\/\/doi.org\/10.1016\/j.path.2019.08.002","journal-title":"Surg Pathol Clin"},{"key":"3752_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1172\/JCI116168","volume":"91","author":"JA Fagin","year":"1993","unstructured":"Fagin JA, Matsuo K, Karmakar A et al (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179\u2013184. https:\/\/doi.org\/10.1172\/JCI116168","journal-title":"J Clin Invest"},{"key":"3752_CR42","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/his.13942","volume":"75","author":"H Duan","year":"2019","unstructured":"Duan H, Li Y, Hu P et al (2019) Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Histopathology 75:890\u2013899. https:\/\/doi.org\/10.1111\/his.13942","journal-title":"Histopathology"},{"key":"3752_CR43","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41379-020-0458-7","volume":"33","author":"RD Chernock","year":"2020","unstructured":"Chernock RD, Rivera B, Borrelli N et al (2020) Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Mod Pathol 33:1264\u20131274. https:\/\/doi.org\/10.1038\/s41379-020-0458-7","journal-title":"Mod Pathol"},{"key":"3752_CR44","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/jamaoncol.2022.1655","volume":"8","author":"J-N Gallant","year":"2022","unstructured":"Gallant J-N, Chen S-C, Ortega CA et al (2022) Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children. JAMA Oncol 8:1323\u20131327. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1655","journal-title":"JAMA Oncol"},{"key":"3752_CR45","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrc3802","volume":"14","author":"WD Foulkes","year":"2014","unstructured":"Foulkes WD, Priest JR, Duchaine TF (2014) DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer 14:662\u2013672. https:\/\/doi.org\/10.1038\/nrc3802","journal-title":"Nat Rev Cancer"},{"key":"3752_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s12022-023-09780-2","volume":"34","author":"G Yegen","year":"2023","unstructured":"Yegen G, Altay AY, Y\u0131lmaz \u0130 et al (2023) DICER1 mutations do not always indicate dismal prognosis in pediatric poorly differentiated thyroid carcinomas. Endocr Pathol 34:279\u2013286. https:\/\/doi.org\/10.1007\/s12022-023-09780-2","journal-title":"Endocr Pathol"},{"key":"3752_CR47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00428-020-02853-1","volume":"477","author":"A Agaimy","year":"2020","unstructured":"Agaimy A, Witkowski L, Stoehr R et al (2020) Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations-is the term \u201cthyroblastoma\u201d more appropriate? Virchows Arch 477:787\u2013798. https:\/\/doi.org\/10.1007\/s00428-020-02853-1","journal-title":"Virchows Arch"},{"key":"3752_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"3752_CR49","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1210\/jc.2013-3842","volume":"99","author":"T Ibrahimpasic","year":"2014","unstructured":"Ibrahimpasic T, Ghossein R, Carlson DL et al (2014) Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab 99:1245\u20131252. https:\/\/doi.org\/10.1210\/jc.2013-3842","journal-title":"J Clin Endocrinol Metab"},{"key":"3752_CR50","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/cancers14051272","volume":"14","author":"L Giovanella","year":"2022","unstructured":"Giovanella L, Deandreis D, Vrachimis A et al (2022) Molecular imaging and theragnostics of thyroid cancers. Cancers (Basel) 14:1272. https:\/\/doi.org\/10.3390\/cancers14051272","journal-title":"Cancers (Basel)"},{"key":"3752_CR51","first-page":"82","volume":"48","author":"L Mansi","year":"2004","unstructured":"Mansi L, Moncayo R, Cuccurullo V et al (2004) Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Q J Nucl Med Mol Imaging 48:82\u201395","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"3752_CR52","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/cancers11091388","volume":"11","author":"F Crispo","year":"2019","unstructured":"Crispo F, Notarangelo T, Pietrafesa M et al (2019) BRAF Inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives. Cancers (Basel) 11:1388. https:\/\/doi.org\/10.3390\/cancers11091388","journal-title":"Cancers (Basel)"},{"key":"3752_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/MNM.0000000000001499","volume":"43","author":"L Xu","year":"2022","unstructured":"Xu L, Zou Q, Jiao J, Zhang Y (2022) Postoperative radioiodine therapy impact on survival in poorly differentiated thyroid carcinoma: a population-based study. Nucl Med Commun 43:145\u2013151. https:\/\/doi.org\/10.1097\/MNM.0000000000001499","journal-title":"Nucl Med Commun"},{"key":"3752_CR54","first-page":"383","volume":"13","author":"M Zhang","year":"2021","unstructured":"Zhang M, Lei S, Chen Y et al (2021) The role of lymph node status in cancer-specific survival and decision-making of postoperative radiotherapy in poorly differentiated thyroid cancer: a population-based study. Am J Transl Res 13:383\u2013390","journal-title":"Am J Transl Res"},{"key":"3752_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647. https:\/\/doi.org\/10.1136\/bmj.g7647","journal-title":"BMJ"},{"key":"3752_CR56","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0003","volume":"12","author":"J Roque","year":"2023","unstructured":"Roque J, Nunes Silva T, Regala C et al (2023) Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma. Eur Thyroid J 12:e230003. https:\/\/doi.org\/10.1530\/ETJ-23-0003","journal-title":"Eur Thyroid J"},{"key":"3752_CR57","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K et al (2021) Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 31:1076\u20131085. https:\/\/doi.org\/10.1089\/thy.2020.0322","journal-title":"Thyroid"},{"key":"3752_CR58","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1089\/thy.2017.0663","volume":"28","author":"F Borson-Chazot","year":"2018","unstructured":"Borson-Chazot F, Dantony E, Illouz F et al (2018) Effect of buparlisib, a pan-class I PI3K inhibitor, in refractory follicular and poorly differentiated thyroid cancer. Thyroid 28:1174\u20131179. https:\/\/doi.org\/10.1089\/thy.2017.0663","journal-title":"Thyroid"},{"key":"3752_CR59","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/. Accessed 17 Sep 2023"},{"key":"3752_CR60","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/14737140.2022.2139680","volume":"22","author":"A Coca-Pelaz","year":"2022","unstructured":"Coca-Pelaz A, Rodrigo JP, Lopez F et al (2022) Evaluating new treatments for anaplastic thyroid cancer. Expert Rev Anticancer Ther 22:1239\u20131247. https:\/\/doi.org\/10.1080\/14737140.2022.2139680","journal-title":"Expert Rev Anticancer Ther"},{"key":"3752_CR61","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","volume":"35","author":"ME Cabanillas","year":"2017","unstructured":"Cabanillas ME, de Souza JA, Geyer S et al (2017) Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II International Thyroid Oncology Group Trial. J Clin Oncol 35:3315\u20133321. https:\/\/doi.org\/10.1200\/JCO.2017.73.0226","journal-title":"J Clin Oncol"},{"key":"3752_CR62","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2265.2006.02712.x","volume":"66","author":"J-D Lin","year":"2007","unstructured":"Lin J-D, Chao T-C, Hsueh C (2007) Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas. Clin Endocrinol (Oxf) 66:224\u2013228. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02712.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3752_CR63","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1507\/endocrj.k06-166","volume":"54","author":"TS Jung","year":"2007","unstructured":"Jung TS, Kim TY, Kim KW et al (2007) Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J 54:265\u2013274. https:\/\/doi.org\/10.1507\/endocrj.k06-166","journal-title":"Endocr J"},{"key":"3752_CR64","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000322640","volume":"79","author":"P Siironen","year":"2010","unstructured":"Siironen P, Hagstr\u00f6m J, M\u00e4enp\u00e4\u00e4 HO et al (2010) Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology 79:400\u2013408. https:\/\/doi.org\/10.1159\/000322640","journal-title":"Oncology"},{"key":"3752_CR65","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/308029","volume":"2011","author":"K Tanaka","year":"2011","unstructured":"Tanaka K, Sonoo H, Saito W et al (2011) Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma. ISRN Endocrinol 2011:308029. https:\/\/doi.org\/10.5402\/2011\/308029","journal-title":"ISRN Endocrinol"},{"key":"3752_CR66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.11604\/pamj.2015.21.137.6720","volume":"21","author":"GS Cherkaoui","year":"2015","unstructured":"Cherkaoui GS, Guensi A, Taleb S et al (2015) Poorly differentiated thyroid carcinoma: a retrospective clinicopathological study. Pan Afr Med J 21:137. https:\/\/doi.org\/10.11604\/pamj.2015.21.137.6720","journal-title":"Pan Afr Med J"},{"key":"3752_CR67","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3803\/EnM.2017.32.2.288","volume":"32","author":"MG Yu","year":"2017","unstructured":"Yu MG, Rivera J, Jimeno C (2017) Poorly differentiated thyroid carcinoma: 10-year experience in a Southeast Asian population. Endocrinol Metab (Seoul) 32:288\u2013295. https:\/\/doi.org\/10.3803\/EnM.2017.32.2.288","journal-title":"Endocrinol Metab (Seoul)"},{"key":"3752_CR68","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2017.12.027","volume":"92","author":"C de la Fouchardi\u00e8re","year":"2018","unstructured":"de la Fouchardi\u00e8re C, Decaussin-Petrucci M, Berthiller J et al (2018) Predictive factors of outcome in poorly differentiated thyroid carcinomas. Eur J Cancer 92:40\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2017.12.027","journal-title":"Eur J Cancer"},{"key":"3752_CR69","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1089\/thy.2019.0263","volume":"29","author":"KS Wong","year":"2019","unstructured":"Wong KS, Lorch JH, Alexander EK et al (2019) Prognostic significance of extent of invasion in poorly differentiated thyroid carcinoma. Thyroid 29:1255\u20131261. https:\/\/doi.org\/10.1089\/thy.2019.0263","journal-title":"Thyroid"},{"key":"3752_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00423-019-01753-6","volume":"404","author":"RA Bichoo","year":"2019","unstructured":"Bichoo RA, Mishra A, Kumari N et al (2019) Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference? Langenbecks Arch Surg 404:45\u201353. https:\/\/doi.org\/10.1007\/s00423-019-01753-6","journal-title":"Langenbecks Arch Surg"},{"key":"3752_CR71","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1097\/PAS.0b013e31822cf962","volume":"35","author":"M Dettmer","year":"2011","unstructured":"Dettmer M, Schmitt A, Steinert H et al (2011) Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? Am J Surg Pathol 35:1866\u20131872. https:\/\/doi.org\/10.1097\/PAS.0b013e31822cf962","journal-title":"Am J Surg Pathol"},{"key":"3752_CR72","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/ERC-22-0151","volume":"29","author":"S Hescot","year":"2022","unstructured":"Hescot S, Al Ghuzlan A, Henry T et al (2022) Prognostic of recurrence and survival in poorly differentiated thyroid cancer. Endocr Relat Cancer 29:625\u2013634. https:\/\/doi.org\/10.1530\/ERC-22-0151","journal-title":"Endocr Relat Cancer"},{"key":"3752_CR73","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al (2022) Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 33:406\u2013415. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014","journal-title":"Ann Oncol"},{"key":"3752_CR74","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"Zhao X, Wang JR, Dadu R et al (2023) Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid 33:484\u2013491. https:\/\/doi.org\/10.1089\/thy.2022.0504","journal-title":"Thyroid"},{"key":"3752_CR75","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL et al (2020) Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol 6:1397\u20131404. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3362","journal-title":"JAMA Oncol"},{"key":"3752_CR76","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, Wirth LJ, Ernst T et al (2020) PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 38:2620\u20132627. https:\/\/doi.org\/10.1200\/JCO.19.02727","journal-title":"J Clin Oncol"},{"key":"3752_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882279","volume":"13","author":"S Jin","year":"2022","unstructured":"Jin S, Liu H, Yang J et al (2022) Development and validation of a nomogram model for cancer-specific survival of patients with poorly differentiated thyroid carcinoma: a SEER database analysis. Front Endocrinol (Lausanne) 13:882279. https:\/\/doi.org\/10.3389\/fendo.2022.882279","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03752-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T09:03:24Z","timestamp":1716195804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03752-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3752"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03752-5","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"type":"print","value":"0945-6317"},{"type":"electronic","value":"1432-2307"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark E. Zafereo reports grant funding from Eli Lilly and Merck to MD Anderson Cancer Center for clinical trials. Other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}